Cargando…
Establishing a whole blood CD4(+) T cell immunity measurement to predict response to anti-PD-1
BACKGROUND: Biomarkers that can accurately predict the efficacy of immune checkpoint inhibitors (ICIs) against programmed death 1 (PD-1) ligand in cancer immunotherapy are urgently needed. We have previously reported a novel formula that predicts the response to treatment with second-line nivolumab...
Autores principales: | Yamaguchi, Ou, Atarashi, Kazuyuki, Yoshimura, Kenichi, Shiono, Ayako, Mouri, Atsuhito, Nishihara, Fuyumi, Miura, Yu, Hashimoto, Kosuke, Miyamoto, Yoshiaki, Uga, Hitoshi, Seki, Nobuo, Matsushima, Tomoko, Kikukawa, Norihiro, Kobayashi, Kunihiko, Kaira, Kyoichi, Kagamu, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9759885/ https://www.ncbi.nlm.nih.gov/pubmed/36528575 http://dx.doi.org/10.1186/s12885-022-10445-2 |
Ejemplares similares
-
Different incidence of interstitial lung disease according to different kinds of EGFR‐tyrosine kinase inhibitors administered immediately before and/or after anti‐PD‐1 antibodies in lung cancer
por: Uchida, Takahiro, et al.
Publicado: (2019) -
Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
por: Shiono, Ayako, et al.
Publicado: (2019) -
Combination of immune check inhibitor and immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis: A case report
por: Kobayashi, Kunihiko, et al.
Publicado: (2021) -
Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
por: Yamaguchi, Ou, et al.
Publicado: (2019) -
Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non‐small cell lung cancer harboring EGFR mutation
por: Yamaguchi, Ou, et al.
Publicado: (2020)